Does the media favor ELAN or DYN?

In the previous week, Dyne Therapeutics had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 17 mentions for Dyne Therapeutics and 10 mentions for Elanco Animal Health. Dyne Therapeutics' average media sentiment score of 0.69 beat Elanco Animal Health's score of 0.67 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ABVX or DYN?

Abivax is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is ABVX or DYN more profitable?

Dyne Therapeutics' return on equity of -61.62% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Dyne Therapeutics N/A -61.62% -49.72%

Does the media favor ABVX or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 17 mentions for Dyne Therapeutics and 13 mentions for Abivax. Abivax's average media sentiment score of 1.44 beat Dyne Therapeutics' score of 0.69 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DYN or AXSM?

In the previous week, Dyne Therapeutics had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for Dyne Therapeutics and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat Dyne Therapeutics' score of 0.69 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, DYN or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is DYN or SMMT more profitable?

Dyne Therapeutics' return on equity of -61.62% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -61.62% -49.72% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to DYN or SMMT?

In the previous week, Dyne Therapeutics had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 17 mentions for Dyne Therapeutics and 14 mentions for Summit Therapeutics. Dyne Therapeutics' average media sentiment score of 0.69 beat Summit Therapeutics' score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend DYN or RDY?

Dyne Therapeutics currently has a consensus price target of $34.42, indicating a potential upside of 36.68%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer DYN or RDY?

In the previous week, Dyne Therapeutics had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 17 mentions for Dyne Therapeutics and 10 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.23 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyne Therapeutics (DYN) Competitors

$25.18 -0.55 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$25.54 +0.37 (+1.45%)

As of 07:34 PM Eastern

Compare

DYN vs. ELAN, ABVX, AXSM, SMMT, and RDY

Should you buy Dyne Therapeutics stock or one of its competitors? MarketBeat compares Dyne Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyne Therapeutics include Elanco Animal Health (ELAN), Abivax (ABVX), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY).

How does Dyne Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Elanco Animal Health has higher revenue and earnings than Dyne Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Dyne Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Dyne Therapeutics	N/A	-61.62%	-49.72%

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Dyne Therapeutics had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 17 mentions for Dyne Therapeutics and 10 mentions for Elanco Animal Health. Dyne Therapeutics' average media sentiment score of 0.69 beat Elanco Animal Health's score of 0.67 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $28.73, indicating a potential upside of 8.72%. Dyne Therapeutics has a consensus price target of $34.42, indicating a potential upside of 36.68%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

Dyne Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Abivax is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

47.9% of Abivax shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dyne Therapeutics' return on equity of -61.62% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Dyne Therapeutics	N/A	-61.62%	-49.72%

Abivax presently has a consensus target price of $156.50, indicating a potential upside of 25.28%. Dyne Therapeutics has a consensus target price of $34.42, indicating a potential upside of 36.68%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 17 mentions for Dyne Therapeutics and 13 mentions for Abivax. Abivax's average media sentiment score of 1.44 beat Dyne Therapeutics' score of 0.69 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dyne Therapeutics beats Abivax on 11 of the 14 factors compared between the two stocks.

How does Dyne Therapeutics compare to Axsome Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Dyne Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Dyne Therapeutics' return on equity of -61.62% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.62%	-49.72%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dyne Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 36.68%. Axsome Therapeutics has a consensus price target of $261.29, indicating a potential upside of 19.86%. Given Dyne Therapeutics' higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Dyne Therapeutics had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for Dyne Therapeutics and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat Dyne Therapeutics' score of 0.69 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than Dyne Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A

Summary

Dyne Therapeutics beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Summit Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Dyne Therapeutics' return on equity of -61.62% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.62%	-49.72%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Dyne Therapeutics had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 17 mentions for Dyne Therapeutics and 14 mentions for Summit Therapeutics. Dyne Therapeutics' average media sentiment score of 0.69 beat Summit Therapeutics' score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Dyne Therapeutics presently has a consensus price target of $34.42, suggesting a potential upside of 36.68%. Summit Therapeutics has a consensus price target of $26.15, suggesting a potential upside of 100.88%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Dyne Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

Summary

Dyne Therapeutics beats Summit Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Dyne Therapeutics (NASDAQ:DYN) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Dr. Reddy's Laboratories has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	26.92

Dyne Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Dyne Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.62%	-49.72%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Dyne Therapeutics currently has a consensus price target of $34.42, indicating a potential upside of 36.68%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Dyne Therapeutics had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 17 mentions for Dyne Therapeutics and 10 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.23 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.70B	$3.52B	$6.83B	$12.41B
Dividend Yield	N/A	3.78%	2.59%	10.11%
P/E Ratio	-7.56	7.45	281.83	23.65
Price / Sales	N/A	1,262.85	585.86	92.89
Price / Cash	N/A	89.39	69.88	58.30
Price / Book	3.70	16.79	10.93	5.84
Net Income	-$446.21M	-$12.44M	$3.49B	$336.16M
7 Day Performance	3.03%	-1.48%	-0.30%	0.03%
1 Month Performance	13.37%	-7.76%	-2.59%	-5.22%
1 Year Performance	155.63%	49.26%	66.21%	17.37%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.4549 of 5 stars	$25.18 -2.1%	$34.42 +36.7%	+159.6%	$4.70B	N/A	N/A	100	Earnings Report Analyst Forecast
ELAN Elanco Animal Health	2.7064 of 5 stars	$25.18 -2.5%	$28.55 +13.4%	+87.5%	$12.90B	$4.72B	N/A	9,400	Positive News Upcoming Earnings
ABVX Abivax	3.9517 of 5 stars	$131.50 -3.8%	$148.54 +13.0%	+75.5%	$11.91B	N/A	N/A	61	Positive News
AXSM Axsome Therapeutics	3.6053 of 5 stars	$221.64 -3.6%	$261.48 +18.0%	+131.7%	$11.84B	$638.50M	N/A	380	Positive News Analyst Forecast
SMMT Summit Therapeutics	3.4595 of 5 stars	$13.50 -2.2%	$26.97 +99.8%	-49.6%	$10.72B	N/A	N/A	110	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. ELAN, ABVX, AXSM, SMMT, and RDY

How does Dyne Therapeutics compare to Elanco Animal Health?

Summary

How does Dyne Therapeutics compare to Abivax?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Summary

How does Dyne Therapeutics compare to Summit Therapeutics?

Summary

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. ELAN, ABVX, AXSM, SMMT, and RDY

How does Dyne Therapeutics compare to Elanco Animal Health?

Which has better valuation & earnings, ELAN or DYN?

Is ELAN or DYN more profitable?

Do institutionals & insiders believe in ELAN or DYN?

Does the media favor ELAN or DYN?

Which has more risk & volatility, ELAN or DYN?

Do analysts recommend ELAN or DYN?

Summary

How does Dyne Therapeutics compare to Abivax?

Which has better valuation and earnings, ABVX or DYN?

Do institutionals and insiders believe in ABVX or DYN?

Is ABVX or DYN more profitable?

Do analysts prefer ABVX or DYN?

Which has more volatility and risk, ABVX or DYN?

Does the media favor ABVX or DYN?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Is DYN or AXSM more profitable?

Do institutionals & insiders believe in DYN or AXSM?

Do analysts recommend DYN or AXSM?

Does the media refer more to DYN or AXSM?

Which has more risk and volatility, DYN or AXSM?

Which has preferable valuation and earnings, DYN or AXSM?

Summary

How does Dyne Therapeutics compare to Summit Therapeutics?

Is DYN or SMMT more profitable?

Does the media refer more to DYN or SMMT?

Do institutionals and insiders hold more shares of DYN or SMMT?

Which has better valuation and earnings, DYN or SMMT?

Do analysts recommend DYN or SMMT?

Which has more risk & volatility, DYN or SMMT?

Summary

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Which has higher earnings and valuation, DYN or RDY?

Which has more risk and volatility, DYN or RDY?

Is DYN or RDY more profitable?

Do analysts recommend DYN or RDY?

Does the media prefer DYN or RDY?

Do institutionals & insiders believe in DYN or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools